Gregg Nyberg

Gregg Nyberg has extensive experience in the biopharmaceutical industry, with a focus on process development and manufacturing operations. Gregg is currently serving as the Chief Technology Officer at Landmark Bio, where they are responsible for designing and building an operations organization for the development and industrialization of novel therapeutics. Prior to this role, Nyberg worked at Merck from 2017 to 2021, where they served as the Associate Vice President and head of Merck Research Labs Biologics Process Research & Development. In this position, they managed a team of scientists and engineers involved in cell line development, process development, technology development, and clinical manufacturing. Before their time at Merck, Nyberg held various positions at Amgen from 2002 to 2017, including Head of Pivotal Cell Sciences & Technology and Process Development Director. At Amgen, they led teams responsible for commercial process development, characterization, and optimization for biopharmaceutical drug substance manufacturing. Nyberg also has experience working at Pfizer, where they served as a Staff Engineer and led process development teams for commercial manufacturing support.

Gregg Nyberg's education history includes a Bachelor of Science (B.S.) degree in Chemical and Petroleum-Refining Engineering from the Colorado School of Mines. Gregg also holds a Doctor of Philosophy (Ph.D.) degree in Chemical Engineering from the Massachusetts Institute of Technology. The specific years of enrollment for both degrees were not provided.